The Private Healthcare Company

PR Newswire | July 24, 2020

DolCas Biotech, LLC, shares its zero-waste goal for the company's entire portfolio of potent branded nutraceutical ingredients. The company declared its commitment to accelerate a full-sustainability strategy centered on the upcycling of typically discarded — yet highly valuable — raw materials. DolCas will further ally this endeavor with its ongoing clean-label initiatives to maintain full transparency and traceability of its product line.According to Euromonitor Internati...

CELL AND GENE THERAPY

Tune Therapeutics | December 03, 2021

Tune Therapeutics, a biotechnology company pioneering the creation of epi-therapeutic medicines, launched today with its powerful and precise genetic tuning platform, TEMPO. This cutting-edge technology dials gene expression up or down to desired levels – with the potential to reverse pathways of cancer, genetic disease, and aging by changing cell fate and function at will. "Genetic medicine is at a tipping point. We now understand that the driving...

INDUSTRIAL IMPACT

Axion BioSystems | February 03, 2022

Axion BioSystems, a leading life sciences tools company focused on advanced bioelectronic assay technologies, announces the acquisition of UK-based printed electronics manufacturer M-Solv Manufacturing Limited, a subsidiary of M-Solv Ltd. The creation of the new division, called Axion BioSystems Manufacturing, UK, Ltd., cements the six-year partnership between the companies and positions Axion for continued growth and innovation. “The need to control th...

Xylyx Bio | August 27, 2020

New York-based Xylyx Bio, a leader in advanced disease models, today announced the release of normal and fibrotic NativeCoat™ human lung- and liver-specific ECM substrates for antifibrotic drug discovery to increase predictiveness of high throughput screening and improve evaluation of efficacy of biopharmaceutical drug candidates for hard to treat fibrotic diseases such as IPF and NASH. Despite billions of dollars spent each year, 9 out of 10 drugs fail to make it to market, in part due to...